BlairMcNamaraMD
Obstetrics & Gynecology • New Haven, CTGynecologic Oncology
Fellow Yale New Haven Hospital
Dr. McNamara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-785-5188Fax+1 203-785-5163
Summary
- Blair McNamara, MD, is an Obstetrics & Gynecology specialist based in New Haven, CT, with a subspeciality in Gynecologic Oncology. After graduating from Yale School of Medicine in 2018, Dr. McNamara completed a residency in Obstetrics and Gynecology at the University of California, San Francisco from 2018 to 2022. She will complete fellowship in Gynecologic Oncology at Yale in 2025. Dr. McNamara also has several publications in prominent medical journals, focusing on treatments for various conditions such as ovarian tumors and cervical cancer, highlighting her extensive research in her field.
Education & Training
University of California (San Francisco)Residency, Obstetrics and Gynecology, 2018 - 2022
Yale School of MedicineClass of 2018
Certifications & Licensure
CT State Medical License 2022 - 2025
CA State Medical License 2019 - 2023
Publications & Presentations
PubMed
- 1 citationsUnmet needs in cervical cancer - can biological therapies plug the gap?Michelle Greenman, Yifan Emily Chang, Blair McNamara, Levent Mutlu, Alessandro D Santin
Expert Opinion on Biological Therapy. 2024-10-01 - Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.Blair McNamara, Michelle Greenman, Stefania Bellone, Luca A Santin, Cem Demirkiran
Gynecologic Oncology. 2024-10-01 - Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovaria...Levent Mutlu, Blair McNamara, Stefania Bellone, Diego D Manavella, Cem Demirkiran
Clinical & Experimental Metastasis. 2024-10-01
Press Mentions
What Are Your Treatment Options for Cervical Cancer?February 10th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
